Evaluation of AMG 420 an antiBCMA bispecific Tcell engager BiTE immunotherapy in patients with RR multiple myeloma

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma

12:48 EDT 6 Jun 2019 | ecancermedicalscience

Prof Max Topp talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from a first in-human phase I dose escalation study using the bispecific antibody construct, AMG 420 in patients with...

More From BioPortfolio on "Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy in patients with R/R multiple myeloma"